David Bearss Resigns as Chief Scientific Officer to Join Huntsman Cancer Institute as Co-director of Center for Investigational Therapeutics

David Bearss Resigns as Chief Scientific Officer to Join Huntsman Cancer Institute as Co-director of Center for Investigational Therapeutics

SuperGen’s MP-470 Demonstrates Clinical Benefit in Small Cell Lung Cancer and Neuroendocrine Tumor Patients

SuperGen’s MP-470 Demonstrates Clinical Benefit in Small Cell Lung Cancer and Neuroendocrine Tumor Patients

SuperGen Presents PIM kinase inhibitor SGI-1776 at American Association for Cancer Research Annual Meeting

SuperGen Presents PIM kinase inhibitor SGI-1776 at American Association for Cancer Research Annual Meeting